[go: up one dir, main page]

WO2003084467A3 - Epitope constructs comprising antigen presenting cell targeting mechanisms - Google Patents

Epitope constructs comprising antigen presenting cell targeting mechanisms Download PDF

Info

Publication number
WO2003084467A3
WO2003084467A3 PCT/US2003/010033 US0310033W WO03084467A3 WO 2003084467 A3 WO2003084467 A3 WO 2003084467A3 US 0310033 W US0310033 W US 0310033W WO 03084467 A3 WO03084467 A3 WO 03084467A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen presenting
presenting cell
cell targeting
epitope constructs
targeting mechanisms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/010033
Other languages
French (fr)
Other versions
WO2003084467A2 (en
Inventor
Ronald M Burch
Daniel A Soltis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to JP2003581707A priority Critical patent/JP2005536987A/en
Priority to IL16428103A priority patent/IL164281A0/en
Priority to MXPA04009554A priority patent/MXPA04009554A/en
Priority to AU2003224819A priority patent/AU2003224819A1/en
Priority to CA002478930A priority patent/CA2478930A1/en
Publication of WO2003084467A2 publication Critical patent/WO2003084467A2/en
Anticipated expiration legal-status Critical
Publication of WO2003084467A3 publication Critical patent/WO2003084467A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to products and methods to elicit a targeted immune response. In particular, the invention relates to epitope constructs that comprise antigen presenting cell-targeting mechanisms.
PCT/US2003/010033 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms Ceased WO2003084467A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003581707A JP2005536987A (en) 2002-04-01 2003-04-01 Epitope construct containing antigen-presenting cell targeting mechanism
IL16428103A IL164281A0 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms
MXPA04009554A MXPA04009554A (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms.
AU2003224819A AU2003224819A1 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms
CA002478930A CA2478930A1 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36945402P 2002-04-01 2002-04-01
US60/369,454 2002-04-01

Publications (2)

Publication Number Publication Date
WO2003084467A2 WO2003084467A2 (en) 2003-10-16
WO2003084467A3 true WO2003084467A3 (en) 2006-07-20

Family

ID=28791953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010033 Ceased WO2003084467A2 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms

Country Status (6)

Country Link
JP (1) JP2005536987A (en)
AU (1) AU2003224819A1 (en)
CA (1) CA2478930A1 (en)
IL (1) IL164281A0 (en)
MX (1) MXPA04009554A (en)
WO (1) WO2003084467A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1511040A (en) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ Alternative spliced forms of proteins underlying multiple therapeutic modalities
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
AU2003263767A1 (en) * 2002-07-03 2004-01-23 Aventis Pasteur Inc. Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
AU2004207233C1 (en) 2003-01-24 2008-04-24 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer
PT1618130E (en) * 2003-04-11 2013-07-04 Survac Aps THERAPEUTIC VACCINE AGAINST CANCER
GB0318247D0 (en) * 2003-08-05 2003-09-10 Royal Veterinary College Antigen delivery system
EP1863529A1 (en) 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
JP5241012B2 (en) * 2005-07-15 2013-07-17 ノバルティス アーゲー PAMPS, pathogen-related molecular pattern
CA2630023A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
MX2009000660A (en) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Influenza vaccine.
PT2476435T (en) * 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS
CN106220721B (en) * 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 PRAME derived peptides and immunogenic compositions comprising the same
WO2009015841A1 (en) * 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP2356131A4 (en) * 2008-12-08 2012-09-12 Tegopharm Corp Masking ligands for reversible inhibition of multivalent compounds
FR2955773B1 (en) * 2010-02-01 2017-05-26 Commissariat Energie Atomique MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CN105209063A (en) * 2013-03-15 2015-12-30 宾夕法尼亚大学理事会 Vaccines having an antigen and interleukin-23 as an adjuvant
US10238741B2 (en) 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
DK3302543T3 (en) * 2015-06-01 2020-05-18 Reber Genetics Co Ltd VACCINE COMPOSITIONS AGAINST PORCINT REPRODUCTION AND RESPIRATION SYNDROME AND PORCINT CIRCOVIRUS-ASSOCIATED DISEASES
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
WO2017165542A1 (en) * 2016-03-22 2017-09-28 University Of Florida Research Foundation, Inc. Methods, kit, and compositions for enhancing cellular therapy
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US20200219586A1 (en) * 2017-06-27 2020-07-09 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center MHC-1 Genotypes Restricts The Oncogenic Mutational Landscape
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FONG L. ET AL.: "Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 15, 17 January 2001 (2001-01-17), pages 8809 - 8814, XP003001078 *
HUARTE E. ET AL.: "Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements", CLIN. CANCER RES., vol. 8, July 2002 (2002-07-01), pages 2336 - 2344, XP002345510 *
NAGORSEN D. ET AL.: "Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her2/neu, and carcinoembryonic antigen in patients with colorectal cancer", CANCER RES., vol. 60, 1 September 2000 (2000-09-01), pages 4850 - 4854, XP003001079 *
THOMSON S.A. ET AL.: "Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design", J. VIROL., vol. 72, no. 3, March 1998 (1998-03-01), pages 2246 - 2252, XP002128492 *
WANG H. ET AL.: "Rapid antibody responses by low-dose, single-step dendritic cell-targeted immunization", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 2, 18 January 2000 (2000-01-18), pages 847 - 852, XP001206541 *

Also Published As

Publication number Publication date
IL164281A0 (en) 2005-12-18
MXPA04009554A (en) 2005-01-25
AU2003224819A1 (en) 2003-10-20
CA2478930A1 (en) 2003-10-16
JP2005536987A (en) 2005-12-08
WO2003084467A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2003084467A3 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
TW200515916A (en) Chimeric antigens for breaking host tolerance to foreign antigens
WO2000056360A3 (en) Vaccine against antigens from bacteriae
WO2005037190A3 (en) Multiplex vaccines
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
ATE381893T1 (en) AROMA PARTICLES
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2003094960A3 (en) Mucosal combination vaccines for bacterial meningitis
IS5329A (en) Antigen transport system where monoglyceride or diglyceride derivatives are adjuvant
WO2003011226A3 (en) Products and drug delivery vehicles
IL184273A0 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
WO2001081609A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2003090696A3 (en) Methods and products for mucosal delivery
WO2004083404A3 (en) Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
AP2005003234A0 (en) Lectin compositions and methods for modulating an immune response to an antigen.
AU2003302235A1 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
WO2002096367A3 (en) Targeted multivalent macromolecules
WO2006090291A3 (en) Method for expanding cd4+ cd25+ t regulatory cells
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
AU2003242535A1 (en) Improved polysaccharide and glycoconjugate vaccines
WO2005035779A3 (en) Method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2478930

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003224819

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003721511

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009554

Country of ref document: MX

Ref document number: 2003581707

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003721511

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)